We describe and characterize a series of polydonal antibodies, generated against amino acid sequences unique to various regions within pro-and mature brain-derived neurotrophic factor (BDNF), a member of the highly conserved nerve growth factor (NGF) family of neurotrophins. Synthetic peptides were coupled to carrier proteins in the presence of glutaraldehyde to restrict the host animals' immune response to epitopes that are compatible with aldehyde fixation. Initial screenings of the reactivity of the antisera were made on brain sections processed for immunohistochemistry after peptide injections into brain parenchyma. As a means of further characterizing these peptide antisera, we have evaluated the reactivity and specificity of the peptide antibodies in BHK cells expressing recombinant pro-and mature BDNF protein from a T7 RNA polymerase-driven ' Vaccinia virus system. Several of the antibodies strongly stained components of cells transfected with the BDNF gene but did not label wild-type cells nor cells containing only the expression vector. It has also been possible to detect differential compartmentalization of the BDNF protein at various stages of processing in the BHK cells, as well as in situ in cryostat sections of brain tissue, with antisera to the pro-and mature protein. We condude that several of our antisera recognize not only the specific peptide immunogens but also what appears to be the corresponding protein native to neurons. ( J Hisrochem Cytochem 41:521-533,   1993) 
Introduction
Many proteins are members of larger, often highly conserved protein families. To determine the cellular distribution of a particular protein one must have specific antibodies that do not crossreact with other family members. With the use of purified proteins it can be difficult to generate antisera that are useful for immunohistochemical localizations, yet which do not crossreact with other similar proteins. Specifically, in the case of the highly conserved NGF family of growth factors, antisera generated against mature NGF have been reported to crossreact with BDNF (1).
One approach to obtain non-crossreactive antisera is to generate monoclonal antibodies (MAb). However, MAb are often difficult to to use for immunohistochemical localization as they recognize a very restricted epitope which may be variably altered by different fixation protocols (6, 11, 42, 43) . In contrast, polyclonal antisera recognize a group of epitopes that often render them more tolerant to side-chain alterations by fixation and processing procedures. Tertiary structural alterations are common when proteins are exposed to aldehyde fixatives, which are known to induce interas well as intramolecular cross-linking of primary amine and thiol groups (143). Alternatively, one can use polyclonal antisera generated to a restricted set of epitopes by immunizing with specific peptide fragments of the protein of interest and thereby limit the pool of potential antigens (9,39). However, peptide antibodies are generated against linear peptides which may not necessarily mimic three-dimensional epitopes of the tertiary protein structure. Antigenic determinants are known to often represent non-linear combinations of amino acids that are not contained in short peptide sequences (10).
The NGF family of neurotrophins (5,41) consists of several highly conserved members, including NGF (25) , BDNF (24) , NT-3 (12, 18, 22, 27, 38) , and NT4/5 (7, 17, 19) . In this study, we have taken the approach of generating polyclonal antibodies against peptides representing the unique regions of BDNF, to exploit specific epitopes and to obtain antisera that do not crossreact with other members of the NGF family of neurotrophins.
A rapid and efficient initial screening for the presence of peptide antisera was made on tissue processed for immunohistochemistry after injection of the cognate peptide into brain parenchyma. Reactive antisera were then characterized for their ability to recognize the parent pro-or mature BDNF in a cell line transfected with and expressing the BDNF gene, as well as on cryostat-sectioned brain tissue with conventional immunohistochemical techniques. We discuss the advantages of using recombinant DNA technology, in complement with conventional histochemical techniques, for characterizing peptide antisera, as well as the various controls necessary to ascertain, as rigorously as possible, the specificity of such antisera.
Materials and Methods
Peptides and Antisera. Five peptide regions, having the lowest degree of sequence similarity to NGF and NT3, were selected from within proand mature BDNF sequences to generate antibodies that could potentially differentiate among the highly conserved NGF family members. In addition to the uniqueness of the peptide sequence (Figure lA) , considerations were also given to hydrophilicity ( Figure 1B) (23) . surface probability (Figure IC) , and predictions of tertiary structure (Figure 2) of the various areas within the BDNF protein from which peptides were derived. It is crucial that the antigenic sites to which antibodies are generated are present on the surface of the mature, folded protein and that these sites are accessible for recognition by the antibodies. As the crystal structure for BDNF is not yet available, determination of hydrophilicity and predictions of surface probability were used to predict which amino acid sequences are most likely to lie on the surface of the mature native BDNF protein and therefore be 1A (PB5) (PB1) ratBDNF .,,VRPNEENHKDA.,, lHSDPARRGll rat NGF ITVDPKLF' KR THPVFHM' rat NT3 IATDT' LLRQQ YAEHKSHR rat NT4 PSTLPPLLFL' TAPAS' * * accessible epitopes for recognition by an antibody. Swissprot and National Biomedical Research Foundation protein databases were searched using FASTA program (32, 33) and analyzed for amino acid homology to exclude any similarities between the selected peptides and other known sequences.
The following peptides were synthesized as carboxy terminal acids using automated, solid-phase methods: BDNF[ -51 to -411 (pB5, a portion of pro-BDNF), BDNF[l-81 (pB1, the amino terminal peptide of mature BDNF), BDNF [40-491 (pB2) , BDNF[91-99] (pB3), and BDNF[59-671 (pB4) (pB2, pB3 and pB4 are contained within areas that are hypothesized to form variable "loop" regions in the mature BDNF protein), (pB1, pB2, pB4 were from Microchemical Facility, Institute for Human Genetics, University of Minnesota, Minneapolis, MN; pB3 and pB5 were from Peninsula Laboratories Europe, St. Helena, UK). Peptides are numbered with respect to the first amino acid residue of mature BDNF. [In our previous report (44) pB2 is referred to as "BDNF173-182".] Each peptide (30 mg) was conjugated to 100 mg of bovine thyroglobulin (Sigma; St Louis, MO) or keyhole limpet hemocyanin (Sigma) in a solution of 0.8% glutaraldehyde in 4 ml of 0.1 M phosphate buffer. The conjugate was dialyzed (Spectrapore dialysis tubing; KEBO, Stockholm, Sweden) (MW cut-off 6000-8000) overnight at 4°C against 0.1 M PBS and diluted with PBS to 1 mg peptide!ml. Five or six rabbits (Table 1) (New Zealand White), (ESF Produkter; Estuna, Sweden) were immunized subcutaneously with 1 mg of each peptide emulsified in Freund's complete adjuvant (Sigma). Rabbits were boosted with approximately 0.5 mg of peptide in Freund's incomplete adjuvant at 2-week intervals for the first 10 weeks and subsequently every 4-6 weeks. Blood was collected 7-10 days after boosting, beginning 9 weeks after initial immunization. This study is based on an evaluation of 8-12 bleeds from each of the 41 rabbits, resulting in 437 different sera.
Specificity of Antisera. Before incubation on tissue, antisera were treated for 2-3 hr at room temperature with their cognate peptide (dissolved in (23) and (C) surface probability plots of BDNF protein generated with sequence analysis software (window of 7) (Macvector; International Biotechnologies, New Haven, CT). These algorithms were used to predict the tertiary structure of BDNF and to ascertain which peptide regions are most likely to lie on the surface of mature BDNF protein (32, 33) . The beginning of mature BDNF is designated as 1. Numbers are assigned with respect to the first amino acid residue of mature BDNF. 50% methanol, 1 mg/ml), cognate peptide conjugated to carrier protein, or carrier protein alone at a concentration of 10 pglml of working dilution of antisera. Antisera treated with the same amount of methanol. omitting peptide, were used as controls. Pre-absorption of the antisera with the specific peptide quenched immunostaining in BHK cells and brain to that of background levels, whereas pre-adsorption of the antisera with the carrier protein did not reduce labeling.
Intracerebral Injection of Peptides and Tissue prepapdtion. Initial screenings of the antisera were made on tissue processed for immunohistochemistry after intraparenchymal injection of peptides pB1-pB5. Rats (150-g female, Sprague-Dawley) (ALAB; Stockholm, Sweden) were anesthetized with halothane and placed in a stereotaxic frame. Each of the peptides (50% methanol, 1 mg/ml) was injected ( 2 PI) into brain parenchyma (striatum).
Fifteen to 30 min later animals were anesthetized with sodium pentobarbital (40 mglkg IP) and perfused via the ascending aorta with 50 ml icecold Ca"-free Tyrode's solution, followed by 200 ml cold formalin-picric acid mixture (4% paraformaldehyde, 0.4% picric acid in 0.16 M phosphate buffer, pH 6.9) (48) . and brains were processed for immunohistochemistry as previously described (20.44) .
Amplification of BDNF Gene. The BDNF coding sequence was amplified by polymerase chain reaction from isolated rat genomic DNA according to standard methods (30) . A 36-mer 5' end oligonucleotide primer (GCC AGA TCT GGA TCC GTG AGA AGA GTG ATG ACC ATC) and a 33-mer 3' end primer (CGG AGA TCT GGA TCC TAA ATC CAC TAT C7T CCC) of the BDNF gene were added to 2 pg of rat genomic DNA. The primers contain cleavage sites for Bgl 11. After 30 cycles of amplification (temperature profile: 9 4 T for 1 min. 55'C for 1 min, 72°C for 2 min), a DNA band of the expected size (760 BP) was obtained and digested with Bgl 11. The BDNF fragment was then cloned into the Bam HI sire of the pGEM-4 expression vector (Promega; Madison, WI) downstream of the T7 promoter. A BDNF-containing clone in the correct orientation was isolated and sequenced completely by the dideoxynucleotide chain termination method (Sequenase; United States Biochemical, Cleveland, OH) (40) .
Expression of BDNF in BHK 21 Cells. Monolayers of BHK 21 (clone 13) cells were grown to 70-80% confluency in MEM supplemented with 10% FCS in 25 cmz flasks for 24 hr before infection. The medium was removed and replaced with serum-free MEM. The cells were infected with the recombinant Vaccinia virus (vTF7-3; kindly provided by Dr. Bernard Moss) at a multiplicity of infection of about 10-20 PFU per cell and incubated at 37°C for 45 min. Cells were infected with vTF7-3 to express the bacteriophage T7 RNA polymerase (16) . Virus inoculum was then removed and replaced by 2 ml of fresh Opti-MEM medium (Gibco, Grand Island, NY and BRL., Gaithersburg, MD). Sixty minutes later the cells were transfected with the recombinant plasmid pGEM4-BDNF using Lipofectin according to the recommended protocol (BRL). Expression of BDNF mRNA was driven by the T7 RNA polymerase.
Immunohistochemistry of BHK Cell Culnues. To allow sufficient time for accumulation of BDNF protein in the transfected BHK cells, cultures were maintained for 6 hr after transfection with pGEM4-BDNF. Previous studies have determined that the recombinant protein is detectable in cytoplasmic compartments at 4 hr after transfection and increases exponentially to level off at 6 hr post transfection (Y. Cao and R. Pettersson, unpublished observations), Culture media were discarded and cells were fixed for 15 min in a formalin-picric acid mixture (4% paraformaldehyde. 0.4% picric acid in 0.16 M phosphate buffer, pH 7.4) (48) and subsequently rinsed three times for 10 min in 0.1 M PBS at room temperature. Primary antisera were diluted 1:lOOO in 0.1 M PBS with 0.3% Triton X-100 and incubated with fixed cultures overnight at 4°C. Culture slides were then rinsed three times for 10 min in 0.1 M PBS, incubated with secondary antisera (FITClabeled goat anti-rabbit 130) (Boehringer Mannheim Scandinavia: Bromma, Sweden) or Cy-+conjugated goat anti-rabbit 1:200) (Jackson Labs; Avondale, PA) for 1 hr at room temperature, rinsed in PBS, and mounted in 90% glycerin in 0.1 PBS with 0.01% p-phenylenediamine to reduce fading (21.35) . Tissues were examined and photographed using epifluorescence microscopy (Nikon-Mikrophot). High-resolution evaluation of BHK cell immunoreactivity was provided by a scanning laser confocal microscope (Bio- 
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Rad, Richmond, CA; MRC-600 equipped with Nikon objective lenses) used as described (45).
Results
In trupurenchy mal Injections of Peptide
Initial screenings of the antisera were made on tissue processed for immunohistochemistry after intraparenchymal injection of peptide ( Figure 3 ). In all of the six immunization groups, two to three of the six rabbits immunized with each peptide produced antibodies that could recognize the synthetic peptide in brain parenchyma ( Table 1 ). The group of antisera directed against pB5 was most successful in detecting the peptide in brain parenchyma. The group of rabbits immunized with pB3 produced antisera that only weakly recognized the injected peptide. Antisera from rabbits that successfully detected peptide injections were then screened on BHK cells. To simplify the evaluation of such a large number of bleeds, antisera that were unsuccessful in detecting the injected peptide were not evaluated further.
Immunohistochemistry of BHK Cell..
Specificity Controls. BDNF-like immunoreactivity was usually detected in a maximum of 2 0 4 0 % of the BHK cells (Figure 4) , consistent with the expected efficiency of transfection. Thus, untransfected cells served as internal specificity controls. No specific immunoreactivity above background levels expected for cell culture was detected in uninfected cells or in cells infected with the vTF7-3 viruses only, omitting the BDNF gene ( Figure 6 ). All BHK cell nuclei were, to various degrees, fluorescent when stained with the secondary antibody alone. Cytoplasmic compartments were unstained when primary antisera were omitted. In all cases discussed in the present study, peptide antibody immunostaining was not abolished by pre-absorption of the antisera with another member of the neurotrophin family (NGF). Moreover, the present antibod- ies did not detect NGF in the male mouse submandibular gland, known to contain high levels of NGF (data not shown). Immunostaining of brain tissue with antisera generated against pB2 was completely abolished by pre-absorption of the antisera with recombinant BDNF (not shown) and these antisera were able to detect recombinant BDNF (generously provided by Y. A. Barde), but not NGF, in Western blot analyses as previously reported (44). Because of the uniqueness of the BDNF peptides used in the present study and the very limited homology with related trophic factors (Table 1) . it is unlikely that these antisera recognize other neurotrophin family members. However, under most conditions it is not possible to ensure monospecificity of an antiserum.
Pro-BDNF Peptide pB5. Antisera against the pB5 peptide corresponding to pro-BDNF ( Figure 2 ) showed the strongest immunoreactivity of all peptide antisera investigated and in all three experimental paradigms (Table 1) . Antisera obtained from four (R69, R71, R72, R73) of the six rabbits immunized with the pB5 region of pro-BDNF resulted in extensive cytoplasmic immunostaining of BHK cells, including a strong reticular perinuclear pattern of immunoreactivity ( Figures SA and 7A ). typical of the endoplasmic reticulum (ER). These pro-BDNF antisera also stained a fine, ER-like granular network which extended from mid soma to peripheral cytoplasmic processes, and which was also revealed with antisera directed against the amino terminal peptide pB1 ( Figures 5B and 7B ). High-resolution images of the ER network stained with both pB5 and pB1 antisera ( Figures 7A and 7B ) revealed reticular aggregates in the perinuclear cytoplasm. This pattern of immunostaining was not generalized to the entire population of BHK cells, was noted only in a subpopulation of cells, and was never detected in cells not transfected with the pGEM4-BDNF construct.
In addition to specific immunostaining of BDNF-expressing BHK cells, some of the pB5 antisera also labeled a cell compartment that appeared to be related to viral infection ( Figure 6) . These inclusions or clusters of brightly fluorescent granules and cytoplasmic fluorescence were not present in the uninfected BHK cells but appeared only when the cells had been infected with Vaccznzovirus and regardless of whether or not the BDNF gene was present. Similar cytoplasmic inclusions were also seen with several antisera generated against other peptides. The immunostaining of putative virusrelated antigens was therefore unrelated to BDNF expression. The immunofluorescence could not be blocked by pre-absorption with the specific peptide immunogen or with the carrier protein. Although no such virus-related antigens were present in normal rat brain, the antisera that immunolabeled these inclusions were not used for further localization of BDNF in brain sections.
Amino-terminal BDNF pB1. Antisera obtained from three of six rabbits immunized with peptide region pB1 ( Figure 2 ) also showed very strong, uniform immunoreactivity in the cytoplasm of BDNF-expressing BHK cells ( Figure 5B ). which included ERtype immunostaining similar to that detected with the pro-BDNF (pB5) antisera (Figure 7) . The immunolabeling of the ER network with pB1 antisera was more restricted and appeared to be more punctate than that of pB5.
pB2. Three of the 12 rabbits immunized with peptide pB2 generated antisera that recognized a subpopulation of BHK cells consistent with the expected transfection rate. Antisera generated against this region showed strong immunoreactivity in the cytoplasm of BDNF-expressing BHK cells, with distinct sparing of areas corresponding to the viral protein aggregates, scattered throughout the cytoplasm ( Figure 5C ). BHK cell nuclei were slightly above back- Figure 6 ); (B) amino-terminal peptide (pB1) antisera (R27G). As detected with pro-BDNF antisera, note fine reticular network extending from strong perinuclear immunofluorescence to cell borders (arrows): (C) pB2 antisera (RlJ). Granular perinuclear cytoplasmic immunoreactivity is noted with antisera to this synthetic peptide representing a sequence within the mature BDNF. Note Figure 6 ). Antisera to both pB2 and pB4 are directed against inner portions of the BDNF protein, and result in similar cytoplasmic immunostaining of BHK cells, excluding the extensive ER network visualized with antisera directed against the amino terminus (pB1) or a portion of pro-BDNF (pB5). Bars = 50 pm. ground levels of immunoreactivity seen with the secondary antibodies alone, while nucleoli appeared dark.
pB3. No convincing cytoplasmic immunostaining was noted with antisera generated against the pB3 region of BDNF protein in BHK cells.
pB4. Three of six rabbits immunized with pB4 produced antisera that could recognize the peptide antigen microinjected into brain parenchyma, but only one (R38) of these antisera was useful in localizing recombinant BDNF in BHK cells ( Figure 5D ). These antisera immunolabeled the cytoplasmic compartment of BHK cells in a pattern similar to that seen with the pB2 antisera: a hazy, granular perinuclear cloud of immunoreactivity with sparing of vacuoles (Figures 5C and 5D ). Neither antiserum displayed the typical ERlike reticular pattern of immunostaining seen with the pB5 or pB1 antisera, raised against pro-BDNF and amino terminal peptides, respectively.
Immunohistochemistry of Brain Tissue
pB5. Immunoreactivity as detected with pB5 antisera was widely distributed in neurons throughout the brain, including hip-pocampus and most cortical areas. Although many of these neurons normally express BDNF mRNA, pB5 immunoreactivity was also detected in many cell populations in which BDNF mRNA has not been detected in the normal adult brain. It therefore appears that although these sera most likely are able to recognize pro-BDNF expressed in neurons, they were unable to selectively detect pro-BDNF in brain parenchyma.
pB2. Antisera generated against pB2 immunolabeled a subpopulation of neurons in the 2-week ( Figure 8) as well as the adult rat brain (Figure 9 ). which appeared to be closely correlated with the reported distribution of BDNF mRNA as revealed by in situ hybridization. Two pB2 antisera immunolabeled somatic, dendritic and, in some areas, nuclear compartments of a subpopulation of neurons in hippocampal and cortical areas in the 2-week ( Figure  8 ) and adult rat brain ( Figure PA) . Notably. in the 2-week brain, granule cells in the outer layer of the dentate gyrus were strongly immunoreactive, while the inner granule cells were very weakly immunoreactive. In the adult, the inner and outer granule cell layers were uniformly immunostained (data not shown). In addition, inverted pyramidal cells of the subplate cortical region were strongly immunoreactive in the 2-week brain, but were no longer present in the adult. related to BDNF expression. Antisera generated against the pB3 region of BDNF resulted in a generalized nuclear immunostaining throughout the brain which was not considered to be related to ) . Therefore, it serves to differentiate the three different types of cells present in these cultures. The asterisk marks fluorescent artifact. Bar = 25 pm.
Figure 6. Fluorescence photomicrograph representative of immunoreactivity detected with peptide antisera (R73F) that crossreacts with viral proteins. Note three cell populations: uninfected control cell (large solid arrow); cells infected with Vaccinia virus and containing immunoreactive viral aggregates (small arrows) apparently unrelated to BDNF expression; and cell infected with Vaccinia virus and transfected with BDNF gene construct showing BDNF peptide immunoreactivity (open arrow) as well as viral aggregates (small arrows). Although this particular antiserum detects putative BDNF expression, it also reacts with viral protein aggregates apparently unrelated to BDNF (see Discussion
Immunostaining with these pB2 antisera (RI, R4. Rbl) also detected cytoplasmic fluorescence in neurons of the basal forebrain ( Figures 9B and 9C ). Two populations of neurons were revealed: the lateral septal neurons and cholinergic neurons in medial septum, the diagonal band, and nucleus basalis. The lateral septal neurons contained a uniform, bright cytoplasmic fluorescence, extending well into the cell processes ( Figure 9B ). The neurons corresponding to the distribution ofcholinergic neurons (i.e., medial septum, diagonal band, and nucleus basalis) exhibited a less intense overall cytoplasmic fluorescence, with marked sparing of the nuclear compartment. In addition, bright aggregates were noted scattered throughout the cytoplasm ( Figure 9C ). pB1, pB4, and pB3. None of these peptides have resulted in antibodies that appear useful for the localization of BDNF in brain tissue. Antisera against pB1 gave no convincing neuronal pattern of BDNF-like immunostaining in brain tissue. One rabbit immunized with pB4 produced an antiserum that resulted in a peculiar membrane immunoreactivity in area CA2 in hippocampus: another rabbit serum reacted with fibers in the internal capsule (not shown). Pre-absorption of the antiserum with pB4 or carrier protein did not block immunostaining. Similar patterns of immunostaining have been detected in pre-immune serum as well as after immunizations with other peptide immunogens unrelated to BDNF (unpublished data), suggesting that this immunoreactivity is un-
The present study provides evidence that antibodies generated against peptide sequences contained within pro-and mature BDNF can be used to detect the parental BDNF protein in two different biological systems. These peptide antisera have been used to detect recombinant BDNF expressed in BHK cells. as well as to detect BDNF endogenously expressed in neurons. Although several of the antisera recognize the respective peptide immunogens when injected acutely into brain parenchyma, only some of these antisera were useful in detecting BDNF ( Table 1) . Because of the extremely low levels of BDNF known to be expressed in neurons in the unperturbed rat brain, the Vaccinia virus system has been used to obtain high-level expression of recombinant BDNF in BHK cells to characterize the specificity and reactivity of BDNF peptide antisera. Peptide antibodies can be a powerful tool for selectively localizing distinct members of closely related proteins, especially in cases where antibodies generated against the native protein are known to crossreact with other related proteins. Generating antibodies against synthetic peptides may also be a viable alternative when the native protein is not available in quantities sufficient for effective immunization protocols. A risk of using peptide antibodies lies in the propensity for such antisera to result in "false negatives" and "false positives," i.e., peptide antibodies may recognize the peptide immunogen but not the complex nature of the parent protein, or they may recognize epitopes not related to the parent protein although containing similar primary sequences. Synthetic peptide immunogens have been selected with the consideration of predicted secondary and tertiary structure of BDNF protein to select sites most likely to be exposed on the native protein (Figure 2 ). Consideration has also been given to select immunogens that contain epitopes which will retain their antigenic integrity after denaturation with standard histochemical fixation (31) .
Localization of pro-BDNF
The most striking immunostaining in BHK cells in this study was obtained with antisera against the pB5 peptide sequence derived from pro-BDNF. A robust cytoplasmic immunoreactivity was evident around the nucleus, and extended throughout the cell soma as a fine reticular meshwork. This network was also detected, although to a more restricted extent, with antisera directed against the amino-terminal peptide of mature BDNF, pB1. The more punctate immunostaining of this cytoplasmic network seen with pB1 can be hypothesized to represent pro-BDNF which has passed through the ER membrane and accumulates in the lumen. The punctate nature of this ER immunostaining seen with pB1 antisera may be attributed to the occurrence of this peptide sequence in more internal regions of pro-BDNF where it may be less accessible for antibody recognition until after cleavage of mature BDNF from pro-BDNF. The punctate immunoreactivity in the ER network may represent aggregates offurther processed BDNF in which the amino terminus of the protein is exposed and is therefore readily accessible to pB1 antibody recognition. The localization of pro-BDNF immunoreactivity in the ER is consistent with established pathways for the transport of secretory proteins, as the antibody binds to the epitope after the protein has crossed the ER membrane. Interestingly, the ER network was immunolabeled only with antibodies directed against the pro-and amino-terminal peptides and not with antisera directed against more internal peptide sequences. Presumably, after protein folding and formation of the disulfide bonds the endoplasmic reticulum was no longer immunolabeled and the BDNF appeared as a diffuse cloud of fluorescence in the perinuclear cytoplasm (Figures 5C and 5D ). pB5 antiserum obtained from R72 also immunoprecipitated recombinant pro-BDNF obtained from cell lysates of Bacufovims cultures with greater efficiency than antisera raised against pB2 (Y. Cao, C. Wetmore, L. Olson, R.F. Pettersson, unpublished data), indicating that the epitope(s) recognized by the pB5 antiserum appear similar in native pro-BDNF and in the aldehyde cross-linked protein detected in cell culture. The success with which pB5 antisera recognize variously treated pro-BDNF may also be due to the occurrence of this peptide in the pro region of the molecule. Thus, the pB5 epitope may remain accessible to the antibodies and not obscured by the three-dimensional folding of the mature protein, as may be the case with the pB3 epitope.
Localization of Mature BDNF
Of the antisera described in this study, the cellular distribution of BDNF immunoreactivity in the brain as determined with pB2 antisera (Rl, R4. R61) was the most consistent with the cellular localization of BDNF mRNA reported by our group and others (13, 15, 18, 34, 46) . Antisera generated against pB2 have been characterized previously in brain tissue and Western blot analysis (44) . A very strong correlation exists between immunohistochemical localization of BDNF with pB2 antisera and the cellular distribution of BDNF mRNA reported in the dentate gyrus ( Figure 8 ) and cortical subplate regions of 2-week-old brains (15) . Of particular interest is the strong immunoreactivity of the outer granule cell layer of the dentate gyrus, as well as the inverted subplate pyramidal cells in cortical areas. Subplate neurons appear only transiently dur- ing development and have also been reported to exhibit NGF receptor immunoreactivity (4). The high levels of BDNF immunoreactivity in these areas during development suggest that BDNF plays a role in axonal outgrowth and in maturation in several cortical areas.
A similar pattern of granular immunoreactivity has been demonstrated in the cytoplasm of BDNF-expressing cells BHK cells and in pyramidal neurons of hippocampus ( Figures 5C and 7B) . A distinct difference in the immunoreactivity of nuclei was observed when comparing the in vitro and in vivo detection of BDNF protein with these antisera. Specifically, antiserum from R1 labeled the nuclear compartments of the population of neurons in the brain thought to express BDNF (Figures 7A and 7B ). yet the nuclei of BDNFexpressing BHK cells were spared (Figure X) . Possible reasons for this difference in immunostaining are, first, that BHK cells differ from neurons and are not believed to express the high affinity tr&B receptor for BDNF. Therefore, they may be unable to internalize and respond to BDNF. Second, the BDNF gene insert used in this study does not contain the potential alternative upstream initiation codon which would result in an additional N-terminal flanking sequence and consequently a possible nuclear translocation in neurons (2). Finally, although the nuclear immunostaining seen in neurons with pB2 antisera satisfies all specificity controls discussed here, it is possible that these antisera recognize an epitope unrelated to BDNF but with a similar distribution in the brain. However, the pB2 antisera do not result in an overall nuclear immunoreactivity of neurons in the brain, nor do they recognize nuclear components of BHK cells, indicating a degree of specificity and selectivity for BDNF-expressing neurons.
A differential immunostaining of the larger neurons in the diagonal band and nucleus basalis, as compared with the smaller neurons in lateral septal area, has been detected with pB2 antisera. The neurons of the diagonal band and nucleus basalis contained latter septal neurons exhibited a stronger and more uniform immunoreactivity of the entire cytoplasm and cell processes, suggest-cytoplasmic clumps resembling lysosomal structures. whereas the ing that these neurons may also synthesize BDNF. It has been shown that BDNFsupports the survival of basal forebrain cholinergic neurons in culture, as well as increases the expression of the cholinergic enzymes acetylcholinesterase and choline acetyltransferase (3). These neurons are believed to internalize BDNF from target areas and to retrogradely transport the trophic factor protein, which can then be detected in the basal forebrain neurons (44) .
Evidence for Dzflerentiul Processing of BDNF in BHK Cells and Neurons
Although antisera generated against pB1 and pB4 strongly stained as in the BHK cells) but which cannot detect BDNF when the level of expression is much lower, as is the case in brain. Alternatively, it may be that BHK cell-expressed BDNF assumes a different conformation from that of neuronal BDNF, thereby exposing the pB4 epitope.
Although the pB4 peptide appears to be hydrophilic, it has very low predictions of surface probability ( Figure 1B) . When the BDNF sequence is compared with the NGF sequence and recent crystal structure, it is noteworthy that pB4 lies within an area corresponding to the part of the NGF molecule that contains three reverse turns (29) . This segment of NGF contains three buried residues with very low side-chain solvent accessibility. Although the crystal structure of BDNF is not yet available, it is believed that the members of the NGF family share a common tertiary structure, owing to the high degree of primary sequence conservation. We speculate that although there exist antibodies against pB4, as evidenced by the immunodetection of injected peptide, the epitopes recog nized by these antibodies are not exposed on the surface of the mature protein but may rather lie buried within the molecule, as has been reported for the corresponding segment of NGF.
One can also speculate that BDNF expressed in the brain may be alternatively processed such that its form and/or conformation differs from that expressed by the BHK cells. It has been determined that the eight amino-terminal amino acid residues are not necessary for biological activity of NGF (26) . In addition, in the determination of the crystal structure of NGF no information was obtained with respect to the amino-terminal residues 1-8, which are known to be susceptible to proteolytic modification. These amino acid residues were absent in 25% of the NGF preparations analyzed (29) . The BDNF-specific pB1 peptide consists of the first eight amino acid residues, analagous to those known to be labile in the NGF protein, and may be cleaved or alternatively processed in neurons. This may result in an inaccessible or nonexistent epitope on the mature BDNF protein, and thereby may explain the lack of immunoreactivity with anti pB1 sera.
The only peptide that did not elicit the production of any antisera that recognized recombinant BDNF in BHK cells or in neurons was pB3. Microinjections of pB3 into brain parenchyma resulted in a weak cloud of immunoreactivity, which indicates that the antisera, in fact, contain antibodies that are reactive with the BDNF specific peptide. However, these antisera were not able to recognize the parent protein. This peptide is the only one that contains two consecutive lysine residues (Figure 2 ), and therefore contains primary amines which are known to be susceptible to cross-linking with aldehyde fixation (8,31). It is likely that the Lys-Lys[228-229] residues participate in aldehyde-induced cross-linking with other portions of the molecule or neighboring proteins and thereby alter the potential antibody recognition site. On the basis of the crystal structure of NGF (29) and BDNF hydrophilicity data ( Figure IB) , we hypothesize that pB3 lies on one of the variable loop regions (Figure 2 ), leaving it exposed and susceptible to fixation-induced cross-linking. In addition, the NGF molecule residues corresponding to BDNF Thgi and 1 3 9 9 participate in main-chain hydrogen bonding (29) , which could be expected to further obstruct antibody access to these residues.
It has been well established that different proteins are variably sensitive to different fixatives (36, 42) and particularly to the duration of exposure to the fixative, as fixation has been reported to continue for 24 hr or more in the presence of some fixatives (14). In attempts to localize low-abundance proteins, it appears that underfixation results in loss of the protein, while overfixation can mask the reactivity of the antigenic sites (36, 37) . It is crucial to evaluate antisera under conditions consistent with those in which the antibodies will be used. How "good" the antiserum may be at recognizing the protein of interest on tissue sections may not be accurately reflected under conditions that require a different kind of epitope recognition by an antibody as, for example, in Western blot or RIA. To generate antisera with the greatest likelihood to recognize paraformaldehyde-altered proteins, the peptides were coupled to carrier proteins in the presence of 8% glutaraldehyde, and therefore the synthetic peptide immunogens will themselves have internal cross-linking and potential antigenic sites will appear to be "fixed," similar to their appearance in situ after fixation.
This study attempts to address several of the risks inherent to the use of peptide antisera in general, and, more specifically, to the immunohistochemical localization of a rare, homologous, and highly conserved protein such as BDNF. Peptide antisera against BDNF have been rigorously characterized and tested by several different means, including the powerful tool of recombinant protein expression. An expression system such as the Gccinia virus-BHK system used in the present study provides a reliable control and a means of characterizing antibodies which can complement other methods used to support immunohistochemical localization, such as convergent localization of the species by antisera or probes from different parts of the molecule. Crossreactivity of an antibody against normal cell components and proteins common to all cells can be easily evaluated in the BHK cells. The selectivity of the immunostaining by an antiserum is strongly supported by the fact that it occurs only in a subset of cells, which express the recombinant protein of interest. Additional corroborative evidence of protein distribution may be obtained by determining the cellular distribution of mRNA with in situ hybridization. Cell cultures are easily and consistently fixed, thereby eliminating some of the difficulties in reproducibility of animal fixation. The BHK cell culture expression system contains rigorous internal controls in the uninfected and untransfected cells and, in addition, significantly minimizes physiological variabilities of neurotrophin levels in in vivo. Therefore, it provides an efficient and consistent means of evaluating antibodies for immunohistochemical localization.
